Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alan C Moss, M.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
2002
Outstanding Abstract Award
2003
Cochrane Fellowship in Systematic Analysis
2004
Travel Award for Young Investigators
2005
Centecor International Research Fellowship in Intestinal Inflammation
2005
Foundation Merit Award
2006
Travel Award
2008
Presidential Award
2010
Fellowship
2011
Abstract of Distinction
2012
Irving W. and Charlotte F. Rabb Endowed Fund for Gastroenterology Research

Overview
Research Interests:
Biologic therapy for Crohn's disease
Molecular response to anti-TNF therapy
Outcomes research in IBD

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R03DK105161 (MOSS, ALAN COLM) Apr 1, 2015 - Mar 31, 2017
    NIH/NIDDK
    Significance of Luminal Exosomes in Inflammatory Bowel Disease (IBD)
    Role: Principal Investigator
  2. K23DK084338 (MOSS, ALAN COLM) May 1, 2011 - Mar 31, 2016
    NIH/NIDDK
    Purinergic Pathways in Crohn's Disease
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Huang J, Kelly CP, Bakirtzi K, Villafuerte Gálvez JA, Lyras D, Mileto SJ, Larcombe S, Xu H, Yang X, Shields KS, Zhu W, Zhang Y, Goldsmith JD, Patel IJ, Hansen J, Huang M, Yla-Herttuala S, Moss AC, Paredes-Sabja D, Pothoulakis C, Shah YM, Wang J, Chen X. Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis. Nat Microbiol. 2019 Feb; 4(2):269-279. PMID: 30510170.
    Citations:    Fields:    
  2. Nassan FL, Korevaar TIM, Coull BA, Skakkebæk NE, Krawetz SA, Estill M, Hait EJ, Korzenik JR, Ford JB, De Poortere RA, Broeren MA, Moss AC, Zoeller TR, Hauser R. Dibutyl-phthalate exposure from mesalamine medications and serum thyroid hormones in men. Int J Hyg Environ Health. 2019 Jan; 222(1):101-110. PMID: 30170956.
    Citations:    Fields:    
  3. Xie A, Robles RJ, Mukherjee S, Zhang H, Feldbrügge L, Csizmadia E, Wu Y, Enjyoji K, Moss AC, Otterbein LE, Quintana FJ, Robson SC, Longhi MS. HIF-1a-induced xenobiotic transporters promote Th17 responses in Crohn's disease. J Autoimmun. 2018 Nov; 94:122-133. PMID: 30098863.
    Citations:    Fields:    
  4. Lin SC, Alonso CD, Moss AC. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature. Transpl Infect Dis. 2018 Dec; 20(6):e12967. PMID: 30011107.
    Citations:    Fields:    Translation:HumansCells
  5. Gubatan J, Moss AC. Vitamin D in inflammatory bowel disease: more than just a supplement. Curr Opin Gastroenterol. 2018 07; 34(4):217-225. PMID: 29762159.
    Citations:    Fields:    
  6. Nielsen OH, Rejnmark L, Moss AC. Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. J Crohns Colitis. 2018 May 25; 12(6):742-752. PMID: 29529167.
    Citations:    Fields:    Translation:Humans
  7. O'Toole A, de Silva PS, Marc LG, Ulysse CA, Testa MA, Ting A, Moss A, Korzenik J, Friedman S. Sexual Dysfunction in Men With Inflammatory Bowel Disease: A New IBD-Specific Scale. Inflamm Bowel Dis. 2018 01 18; 24(2):310-316. PMID: 29361102.
    Citations:    Fields:    
  8. Gubatan J, Mitsuhashi S, Longhi MS, Zenlea T, Rosenberg L, Robson S, Moss AC. Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis. Cytokine. 2018 03; 103:38-45. PMID: 29324259.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  9. Gonzalez-Suarez B, Sengupta S, Moss AC. Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis. World J Gastroenterol. 2017 Dec 07; 23(45):8082-8089. PMID: 29259384.
    Citations:    Fields:    Translation:Humans
  10. Juncadella AC, Moss A. Fecal microbiota transplantation as a possible treatment of irritable bowel syndrome. Ann Transl Med. 2017 Dec; 5(24):506. PMID: 29299467.
    Citations: 1     
  11. Boyle MP, Moss AC, O'Toole AM, Vaughn B, Cheifetz AS. C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab. J Dig Dis. 2017 Dec; 18(12):678-683. PMID: 29119722.
    Citations:    Fields:    Translation:Humans
  12. Nassan FL, Coull BA, Skakkebaek NE, Andersson AM, Williams MA, Mínguez-Alarcón L, Krawetz SA, Hall JE, Hait EJ, Korzenik JR, Ford JB, Moss AC, Hauser R. A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and serum reproductive hormones in men. Environ Res. 2018 01; 160:121-131. PMID: 28978458.
    Citations: 2     Fields:    Translation:Humans
  13. Feldbrügge L, Moss AC, Yee EU, Csizmadia E, Mitsuhashi S, Longhi MS, Sandhu B, Stephan H, Wu Y, Cheifetz AS, Müller CE, Sévigny J, Robson SC, Jiang ZG. Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. J Crohns Colitis. 2017 Sep 01; 11(9):1113-1123. PMID: 28472257.
    Citations: 1     Fields:    Translation:HumansAnimals
  14. Flores BM, O'Connor A, Moss AC. Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. Gastrointest Endosc. 2017 Dec; 86(6):1006-1011.e8. PMID: 28750838.
    Citations: 1     Fields:    Translation:Humans
  15. Longhi MS, Moss A, Jiang ZG, Robson SC. Purinergic signaling during intestinal inflammation. J Mol Med (Berl). 2017 Sep; 95(9):915-925. PMID: 28547076.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  16. Longhi MS, Vuerich M, Kalbasi A, Kenison JE, Yeste A, Csizmadia E, Vaughn B, Feldbrugge L, Mitsuhashi S, Wegiel B, Otterbein L, Moss A, Quintana FJ, Robson SC. Bilirubin suppresses Th17 immunity in colitis by upregulating CD39. JCI Insight. 2017 May 04; 2(9). PMID: 28469075.
    Citations: 2     Fields:    
  17. Gubatan JMB, Moss AC. Reply. Clin Gastroenterol Hepatol. 2017 07; 15(7):1136-1137. PMID: 28377073.
    Citations:    Fields:    
  18. Gianotti RJ, Moss AC. Fecal Microbiota Transplantation: From Clostridium difficile to Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2017 Apr; 13(4):209-213. PMID: 28546791.
    Citations: 7     
  19. Cury DB, de Souza AW, Vianna GA, Odashiro D, Farias A, Moss AC. Cutaneous Vasculitis in a Patient with Crohn's Disease Treated with Adalimumab. Inflamm Bowel Dis. 2017 01; 23(1):E1-E2. PMID: 27893546.
    Citations:    Fields:    Translation:Humans
  20. Gianotti RJ, Moss AC. The Use and Efficacy of Fecal Microbiota Transplantation for Refractory Clostridium difficile in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 11; 22(11):2704-2710. PMID: 27755271.
    Citations:    Fields:    Translation:HumansCells
  21. Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, Gevers D, Ting A, Robson SC, Moss AC. Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. Inflamm Bowel Dis. 2016 09; 22(9):2182-90. PMID: 27542133.
    Citations: 18     Fields:    Translation:HumansCells
  22. Nassan FL, Coull BA, Skakkebaek NE, Williams MA, Dadd R, Mínguez-Alarcón L, Krawetz SA, Hait EJ, Korzenik JR, Moss AC, Ford JB, Hauser R. A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease. Environ Int. 2016 10; 95:120-30. PMID: 27575365.
    Citations: 2     Fields:    Translation:Humans
  23. Patil DT, Moss AC, Odze RD. Role of Histologic Inflammation in the Natural History of Ulcerative Colitis. Gastrointest Endosc Clin N Am. 2016 Oct; 26(4):629-40. PMID: 27633592.
    Citations: 2     Fields:    Translation:Humans
  24. Mitsuhashi S, Feldbrügge L, Csizmadia E, Mitsuhashi M, Robson SC, Moss AC. Luminal Extracellular Vesicles (EVs) in Inflammatory Bowel Disease (IBD) Exhibit Proinflammatory Effects on Epithelial Cells and Macrophages. Inflamm Bowel Dis. 2016 07; 22(7):1587-95. PMID: 27271497.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  25. Gubatan J, Mitsuhashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2017 02; 15(2):240-246.e1. PMID: 27266980.
    Citations: 8     Fields:    Translation:Humans
  26. Zenlea T, Yee EU, Rosenberg L, Boyle M, Nanda KS, Wolf JL, Falchuk KR, Cheifetz AS, Goldsmith JD, Moss AC. Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. Am J Gastroenterol. 2016 05; 111(5):685-90. PMID: 26977756.
    Citations: 16     Fields:    Translation:Humans
  27. Moore C, Corbett G, Moss AC. Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease. J Crohns Colitis. 2016 May; 10(5):619-25. PMID: 26763722; PMCID: PMC4957454.
    Citations: 14     Fields:    Translation:Humans
  28. Boyle M, Ting A, Cury DB, Nanda K, Cheifetz AS, Moss A. Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015 Dec; 21(12):2873-8. PMID: 26313693.
    Citations: 2     Fields:    Translation:Humans
  29. Gibson DJ, Elliott L, McDermott E, Tosetto M, Keegan D, Byrne K, Martin ST, Rispens T, Cullen G, Mulcahy HE, Cheifetz AS, Moss AC, Robson SC, Doherty GA, Ryan EJ. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Dec; 21(12):2806-14. PMID: 26332314.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  30. Bai A, Moss A, Rothweiler S, Longhi MS, Wu Y, Junger WG, Robson SC. NADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine. Nat Commun. 2015 Nov 09; 6:8819. PMID: 26549640; PMCID: PMC4667632.
    Citations: 12     Fields:    Translation:HumansCells
  31. O'Connor A, Packey CD, Akbari M, Moss AC. Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Nov; 21(11):2562-9. PMID: 26296062.
    Citations: 1     Fields:    Translation:Humans
  32. Sahi KS, Lee KS, Moss A, Yee E, Allard F, Brook A, Mortele KJ. MR Enterography of the Ileoanal Pouch: Descriptive Radiologic Analysis With Endoscopic and Pathologic Correlation. AJR Am J Roentgenol. 2015 Nov; 205(5):W478-84. PMID: 26496569.
    Citations: 1     Fields:    Translation:Humans
  33. Abhyankar A, Moss AC. Iron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Aug; 21(8):1976-81. PMID: 25844962.
    Citations: 2     Fields:    Translation:Humans
  34. O'Toole A, Moss AC. Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease. Curr Gastroenterol Rep. 2015 Aug; 17(8):32. PMID: 26188882.
    Citations: 5     Fields:    Translation:Humans
  35. Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015 Feb; 3(1):63-8. PMID: 25567472; PMCID: PMC4324872.
    Citations: 16     
  36. Leyden JE, Moss AC, MacMathuna P. Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev. 2014; (12):CD005046. PMID: 25485740.
    Citations: 11     Fields:    Translation:Humans
  37. Moss AC. Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. Aliment Pharmacol Ther. 2014 Nov; 40(10):1249. PMID: 25303382.
    Citations:    Fields:    Translation:Humans
  38. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014 Nov; 20(11):1996-2003. PMID: 25192499.
    Citations: 33     Fields:    Translation:Humans
  39. Franquet E, Palmer MR, Gifford AE, Selen DJ, Chen YC, Sedora-Roman N, Joyce RM, Kolodny GM, Moss AC. Rifaximin suppresses background intestinal 18F-FDG uptake on PET/CT scans. Nucl Med Commun. 2014 Oct; 35(10):1026-31. PMID: 25076161.
    Citations: 5     Fields:    Translation:Humans
  40. Bai A, Moss A, Kokkotou E, Usheva A, Sun X, Cheifetz A, Zheng Y, Longhi MS, Gao W, Wu Y, Robson SC. CD39 and CD161 modulate Th17 responses in Crohn's disease. J Immunol. 2014 Oct 01; 193(7):3366-77. PMID: 25172498; PMCID: PMC4170017.
    Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
  41. Jiang ZG, Wu Y, Csizmadia E, Feldbrügge L, Enjyoji K, Tigges J, Toxavidis V, Stephan H, Müller CE, Müller CE, McKnight CJ, Moss A, Robson SC. Characterization of circulating microparticle-associated CD39 family ecto-nucleotidases in human plasma. Purinergic Signal. 2014 Dec; 10(4):611-8. PMID: 25165006; PMCID: PMC4272360.
    Citations: 5     Fields:    Translation:HumansCells
  42. Cury DB, Moss AC. Treatment of Crohn's disease in pregnant women: drug and multidisciplinary approaches. World J Gastroenterol. 2014 Jul 21; 20(27):8790-5. PMID: 25083053; PMCID: PMC4112876.
    Citations:    Fields:    Translation:HumansPHPublic Health
  43. Moss AC. The meaning of low-grade inflammation in clinically quiescent inflammatory bowel disease. Curr Opin Gastroenterol. 2014 Jul; 30(4):365-9. PMID: 24811053.
    Citations: 4     Fields:    Translation:Humans
  44. Feuerstein JD, Shah S, Najarian R, Nagle D, Moss AC. A fatal case of diffuse enteritis after colectomy for ulcerative colitis: a case report and review of the literature. Am J Gastroenterol. 2014 Jul; 109(7):1086-9. PMID: 24989103.
    Citations: 1     Fields:    Translation:Humans
  45. Moss AC, Lillis Y, Edwards George JB, Choudhry NK, Berg AH, Cheifetz AS, Horowitz G, Leffler DA. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol. 2014 Dec; 109(12):1850-5. PMID: 24913040.
    Citations: 2     Fields:    Translation:Humans
  46. Ham M, Longhi MS, Lahiff C, Cheifetz A, Robson S, Moss AC. Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. Inflamm Bowel Dis. 2014 May; 20(5):856-60. PMID: 24681654.
    Citations: 10     Fields:    Translation:HumansCells
  47. Sura SP, Ahmed A, Cheifetz AS, Moss AC. Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. J Clin Gastroenterol. 2014 Apr; 48(4):351-5. PMID: 24492405; PMCID: PMC3956001.
    Citations: 1     Fields:    Translation:HumansAnimals
  48. O'Connor A, Moss AC. Current and emerging maintenance therapies for ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2014 May; 8(4):359-68. PMID: 24650224.
    Citations: 1     Fields:    Translation:Humans
  49. Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. J Manag Care Spec Pharm. 2014 Mar; 20(3):309-14. PMID: 24564811.
    Citations: 2     Fields:    Translation:Humans
  50. Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model. Inflamm Bowel Dis. 2014 Mar; 20(3):545-52. PMID: 24407484.
    Citations: 13     Fields:    Translation:Humans
  51. Moss AC. Residual inflammation and ulcerative colitis in remission. Gastroenterol Hepatol (N Y). 2014 Mar; 10(3):181-3. PMID: 24829545; PMCID: PMC4014050.
    Citations: 1     
  52. Vaughn BP, Moss AC. Prevention of post-operative recurrence of Crohn's disease. World J Gastroenterol. 2014 Feb 07; 20(5):1147-54. PMID: 24574791; PMCID: PMC3921499.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  53. Longhi MS, Moss A, Bai A, Wu Y, Huang H, Cheifetz A, Quintana FJ, Robson SC. Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. PLoS One. 2014; 9(2):e87956. PMID: 24505337; PMCID: PMC3914873.
    Citations: 16     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  54. O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014 Jan; 20(1):1-6. PMID: 24280879.
    Citations: 25     Fields:    Translation:Humans
  55. Moss AC. Therapeutic drug monitoring, mucosal healing, deep remission: the path to nirvana in Crohn's disease? Clin Gastroenterol Hepatol. 2014 Mar; 12(3):432-3. PMID: 24370555.
    Citations: 3     Fields:    Translation:Humans
  56. Safaie P, Ham M, Kuang P, Mehta AS, Wang M, Cheifetz AS, Robson S, Lau D, Block TM, Moss AC. Lectin-reactive anti-a-gal in patients with Crohn's disease: correlation with clinical phenotypes. Inflamm Bowel Dis. 2013 Dec; 19(13):2796-800. PMID: 24185312.
    Citations:    Fields:    Translation:Humans
  57. Vaughn BP, Moss AC. Novel treatment options for ulcerative colitis. Clin Investig (Lond). 2013 Nov; 3(11):1057-1069. PMID: 24533177.
    Citations:    
  58. Cury DB, Moss AC, Schor N. Nephrolithiasis in patients with inflammatory bowel disease in the community. Int J Nephrol Renovasc Dis. 2013; 6:139-42. PMID: 23935383; PMCID: PMC3735273.
    Citations: 5     
  59. Moss AC. True costs of infliximab testing and administration. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):346. PMID: 23811252.
    Citations:    Fields:    Translation:Humans
  60. Ham M, Moss A. Oral ertapenem for refractory pouchitis. J Crohns Colitis. 2013 Nov; 7(10):e501-2. PMID: 23694856.
    Citations: 1     Fields:    Translation:Humans
  61. Ferreira J, Akbari M, Gashin L, Cullen G, Moss A, Leffler DA, Aronson M, Cheifetz AS. Prevalence and lifetime risk of endoscopy-related complications among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Oct; 11(10):1288-93. PMID: 23669305.
    Citations: 1     Fields:    Translation:Humans
  62. Cury DB, Mizsputen SJ, Versolato C, Miiji LO, Pereira E, Delboni MA, Schor N, Moss AC. Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. Cell Immunol. 2013 Mar; 282(1):66-70. PMID: 23685388; PMCID: PMC4080304.
    Citations: 10     Fields:    Translation:HumansAnimals
  63. Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, Wolf JL, Cheifetz AS, Goldsmith JD, Moss AC. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol. 2013 Aug; 11(8):991-6. PMID: 23591275; PMCID: PMC3753658.
    Citations: 16     Fields:    Translation:Humans
  64. Moss AC. Prevention of postoperative recurrence of Crohn's disease: what does the evidence support? Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):856-9. PMID: 23446339.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  65. Metz AJ, Bourke MJ, Moss A, Dower A, Zarzour P, Hawkins NJ, Ward RL, Hesson LB. A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations. Eur J Gastroenterol Hepatol. 2013 Mar; 25(3):319-26. PMID: 23354161.
    Citations: 2     Fields:    Translation:Humans
  66. Rosenberg L, Lawlor GO, Zenlea T, Goldsmith JD, Gifford A, Falchuk KR, Wolf JL, Cheifetz AS, Robson SC, Moss AC. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):779-84. PMID: 23446338.
    Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
  67. Gifford A, Moss AC. Comment on Moshkovska et al. Inflamm Bowel Dis. 2013 Feb; 19(2):E19. PMID: 22179973.
    Citations:    Fields:    Translation:Humans
  68. Swan MP, Alexander S, Moss A, Williams SJ, Ruppin D, Hope R, Bourke MJ. Needle knife sphincterotomy does not increase the risk of pancreatitis in patients with difficult biliary cannulation. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):430-436.e1. PMID: 23313840.
    Citations: 8     Fields:    Translation:Humans
  69. Gifford AE, Berg AH, Lahiff C, Cheifetz AS, Horowitz G, Moss AC. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Am J Gastroenterol. 2013 Feb; 108(2):249-55. PMID: 23295279.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  70. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013 Jan; 108(1):40-7; quiz 48. PMID: 23147525; PMCID: PMC3561464.
    Citations: 73     Fields:    Translation:Humans
  71. Doherty GA, Bai A, Hanidziar D, Longhi MS, Lawlor GO, Putheti P, Csizmadia E, Nowak M, Cheifetz AS, Moss AC, Robson SC. CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. Eur J Immunol. 2012 Nov; 42(11):3062-72. PMID: 22965858; PMCID: PMC3556646.
    Citations: 12     Fields:    Translation:HumansCells
  72. Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012 Oct 17; 10:CD008424. PMID: 23076948.
    Citations: 8     Fields:    Translation:Humans
  73. Moss A. Colonic tattooing: the revival of a black art? Gastrointest Endosc. 2012 Oct; 76(4):801-3. PMID: 22985644.
    Citations: 1     Fields:    Translation:Humans
  74. Bassan MS, Holt B, Moss A, Williams SJ, Sonson R, Bourke MJ. Carbon dioxide insufflation reduces number of postprocedure admissions after endoscopic resection of large colonic lesions: a prospective cohort study. Gastrointest Endosc. 2013 Jan; 77(1):90-5. PMID: 22867448.
    Citations: 8     Fields:    Translation:Humans
  75. Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol. 2012; 4:41-50. PMID: 22888278; PMCID: PMC3413022.
    Citations: 2     
  76. Wang K, Chen YC, Palmer MR, Tal I, Ahmed A, Moss AC, Kolodny GM. Focal physiologic fluorodeoxyglucose activity in the gastrointestinal tract is located within the colonic lumen. Nucl Med Commun. 2012 Jun; 33(6):641-7. PMID: 22240934.
    Citations: 3     Fields:    Translation:Humans
  77. Moss AC. Commentary: outcomes after escalation of infliximab in moderately active ulcerative colitis - author's reply. Aliment Pharmacol Ther. 2012 Apr; 35(8):958-9. PMID: 22436037.
    Citations:    
  78. Doherty G, Moss AC. 5-aminosalicylates to prevent relapse of Crohn's disease after surgery. Am J Gastroenterol. 2012 Mar; 107(3):487; author reply 487-8. PMID: 22388032.
    Citations:    Fields:    Translation:Humans
  79. Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012 Mar; 5(2):113-23. PMID: 22390554; PMCID: PMC3314328.
    Citations: 12     Fields:    Translation:Humans
  80. Pallav K, Leffler DA, Bennett M, Tariq S, Xu H, Kabbani T, Moss AC, Dennis M, Kelly CP, Schuppan D. Open conformation tissue transglutaminase testing for celiac dietary assessment. Dig Liver Dis. 2012 May; 44(5):375-8. PMID: 22261352; PMCID: PMC3384702.
    Citations: 2     Fields:    Translation:Humans
  81. Rostholder E, Ahmed A, Cheifetz AS, Moss AC. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther. 2012 Mar; 35(5):562-7. PMID: 22239070; PMCID: PMC3277945.
    Citations: 11     Fields:    Translation:Humans
  82. Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis. 2012 Jun; 18(6):1057-63. PMID: 21953829.
    Citations: 17     Fields:    Translation:HumansCells
  83. Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflamm Bowel Dis. 2012 Sep; 18(9):1608-16. PMID: 21905173.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  84. Cullen G, Vaughn B, Ahmed A, Peppercorn MA, Smith MP, Moss AC, Cheifetz AS. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. Inflamm Bowel Dis. 2012 Apr; 18(4):691-6. PMID: 21648022.
    Citations: 7     Fields:    Translation:Humans
  85. Lahiff C, Moss AC. Cyclosporine in the management of severe ulcerative colitis while breast-feeding. Inflamm Bowel Dis. 2011 Jul; 17(7):E78. PMID: 21538721.
    Citations: 1     Fields:    Translation:Humans
  86. Doherty GA, Moss AC, Cheifetz AS. Capsule endoscopy for small-bowel evaluation in Crohn's disease. Gastrointest Endosc. 2011 Jul; 74(1):167-75. PMID: 21497806.
    Citations: 12     Fields:    Translation:Humans
  87. Lahiff C, Moss AC. Curcumin for clinical and endoscopic remission in ulcerative colitis. Inflamm Bowel Dis. 2011 Jul; 17(7):E66. PMID: 21484966.
    Citations: 9     Fields:    Translation:Humans
  88. Lahiff C, Kane S, Moss AC. Drug development in inflammatory bowel disease: the role of the FDA. Inflamm Bowel Dis. 2011 Dec; 17(12):2585-93. PMID: 21484967.
    Citations: 3     Fields:    Translation:Humans
  89. Cheifetz AS, Stern J, Garud S, Goldstein E, Malter L, Moss AC, Present DH. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol. 2011 Feb; 45(2):107-12. PMID: 20679905.
    Citations: 10     Fields:    Translation:Humans
  90. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010 Sep; 16(9):1620-7. PMID: 20232408.
    Citations: 64     Fields:    Translation:HumansCells
  91. Doherty GA, Moss AC, Cheifetz AS. Capsule endoscopy in suspected Crohn's disease: "yield" does not equal "diagnosis". Am J Gastroenterol. 2010 Sep; 105(9):2111; author reply 2111-2. PMID: 20818355.
    Citations: 3     Fields:    Translation:Humans
  92. Cury DB, Moss AC. Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010 Aug; 16(8):1393-6. PMID: 19998457.
    Citations: 6     Fields:    Translation:Humans
  93. Lawlor G, Ahmed A, Moss AC. Once-daily mesalamine granules for ulcerative colitis. Expert Rev Clin Immunol. 2010 Jul; 6(4):521-6. PMID: 20594123.
    Citations: 1     Fields:    Translation:Humans
  94. Cury DB, Moss AC, Elias G, Nakao A. Adalimumab for cutaneous metastatic Crohn's disease. Inflamm Bowel Dis. 2010 May; 16(5):723-4. PMID: 19728388.
    Citations: 1     Fields:    Translation:Humans
  95. Moss AC. CMV in moderately active colitis: much ado about nothing? Dig Dis Sci. 2010 Apr; 55(4):880-2. PMID: 20204696.
    Citations:    Fields:    Translation:Humans
  96. Doherty GA, Bennett GC, Cheifetz AS, Moss AC. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment Pharmacol Ther. 2010 Apr; 31(8):802-9. PMID: 20055785.
    Citations: 13     Fields:    Translation:HumansPHPublic Health
  97. Lawlor G, Moss AC. Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. Clin Exp Gastroenterol. 2009; 2:149-61. PMID: 21694839; PMCID: PMC3108644.
    Citations: 2     
  98. Moss AC, Chaudhary N, Tukey M, Junior J, Cury D, Falchuk KR, Cheifetz AS. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. J Crohns Colitis. 2010 Jun; 4(2):171-5. PMID: 21122501.
    Citations: 8     Fields:    Translation:Humans
  99. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev. 2009 Oct 07; (4):CD006873. PMID: 19821389.
    Citations: 43     Fields:    Translation:HumansPHPublic Health
  100. Tukey M, Pleskow D, Legnani P, Cheifetz AS, Moss AC. The utility of capsule endoscopy in patients with suspected Crohn's disease. Am J Gastroenterol. 2009 Nov; 104(11):2734-9. PMID: 19584828.
    Citations: 23     Fields:    Translation:Humans
  101. Moss AC, Kim KJ, Fernandez-Becker N, Cury D, Cheifetz AS. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci. 2010 May; 55(5):1413-20. PMID: 19533357.
    Citations: 5     Fields:    Translation:Humans
  102. Mehta BP, Shmerling RH, Moss AC. Pseudogout after polyethylene glycol bowel cleansing. J Clin Gastroenterol. 2009 Jan; 43(1):95-6. PMID: 18528291.
    Citations: 1     Fields:    Translation:Humans
  103. Fernandez-Becker NQ, Moss AC. In silico analysis of T-bet activity in peripheral blood mononuclear cells in patients with inflammatory bowel disease (IBD). In Silico Biol. 2009; 9(5-6):355-63. PMID: 22430437.
    Citations: 4     Fields:    Translation:HumansCells
  104. Moss AC, Cheifetz AS. How often is a diagnosis of ulcerative colitis changed to Crohn's disease and vice versa? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S155-6. PMID: 18816774.
    Citations: 4     Fields:    Translation:Humans
  105. Kokkotou E, Moss AC, Torres D, Karagiannides I, Cheifetz A, Liu S, O'Brien M, Maratos-Flier E, Pothoulakis C. Melanin-concentrating hormone as a mediator of intestinal inflammation. Proc Natl Acad Sci U S A. 2008 Jul 29; 105(30):10613-8. PMID: 18650383; PMCID: PMC2492477.
    Citations: 23     Fields:    Translation:HumansAnimals
  106. Koon HW, Zhao D, Xu H, Bowe C, Moss A, Moyer MP, Pothoulakis C. Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. Am J Pathol. 2008 Aug; 173(2):400-10. PMID: 18599605; PMCID: PMC2475777.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  107. Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther. 2008 Jul; 28(2):221-7. PMID: 18485127.
    Citations: 8     Fields:    Translation:Humans
  108. Patil SA, Moss AC. Balsalazide disodium for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2008 Apr; 2(2):177-84. PMID: 19072352.
    Citations: 1     Fields:    Translation:Humans
  109. Kokkotou E, Moss AC, Michos A, Espinoza D, Cloud JW, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother. 2008 Mar; 52(3):1121-6. PMID: 18195066; PMCID: PMC2258528.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  110. Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs. 2008; 68(8):1089-103. PMID: 18484800.
    Citations: 9     Fields:    
  111. Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008; 68(9):1157-67. PMID: 18547130.
    Citations: 8     Fields:    Translation:Humans
  112. Moss AC, Morris E, Leyden J, MacMathuna P. Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol. 2007 Dec; 19(12):1119-24. PMID: 17998839.
    Citations: 36     Fields:    Translation:Humans
  113. Moss AC, Callery MP, Falchuk KR. Gastrointestinal [corrected] stromal tumor of the ampulla of vater mimicking a duodenal ulcer. Clin Gastroenterol Hepatol. 2007 Oct; 5(10):A26. PMID: 17916534.
    Citations: 1     Fields:    Translation:Humans
  114. Moss AC, Cheifetz AS. Reducing the torment of diarrhea: tormentil for active ulcerative colitis. J Clin Gastroenterol. 2007 Oct; 41(9):797-8. PMID: 17881923.
    Citations: 1     Fields:    Translation:HumansAnimals
  115. Murray D, Doran P, MacMathuna P, Moss AC. In silico gene expression analysis--an overview. Mol Cancer. 2007 Aug 07; 6:50. PMID: 17683638; PMCID: PMC1964762.
    Citations: 16     Fields:    
  116. Moss AC, Farrell RJ. Impotent immune system: an underlying problem in Crohn's disease. Gastroenterology. 2007 Jun; 132(7):2609-11. PMID: 17570236.
    Citations: 1     Fields:    
  117. Moss AC. Curcumin for maintenance therapy in ulcerative colitis. Clin Gastroenterol Hepatol. 2007 May; 5(5):642; author reply 642. PMID: 17478350.
    Citations: 1     Fields:    Translation:Humans
  118. Moss AC, Anton P, Savidge T, Newman P, Cheifetz AS, Gay J, Paraschos S, Winter MW, Moyer MP, Karalis K, Kokkotou E, Pothoulakis C. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut. 2007 Sep; 56(9):1210-7. PMID: 17412781; PMCID: PMC1954994.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  119. Moss AC, Kelly CP. Reflux, dyspepsia, and disorders of the foregut. South Med J. 2007 Mar; 100(3):266-72; quiz 273, 294. PMID: 17396730.
    Citations:    Fields:    Translation:Humans
  120. Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf. 2007 Mar; 6(2):99-107. PMID: 17367256.
    Citations: 13     Fields:    Translation:HumansAnimals
  121. Moss AC, Doran PP, Macmathuna P. In Silico Promoter Analysis can Predict Genes of Functional Relevance in Cell Proliferation: Validation in a Colon Cancer Model. Transl Oncogenomics. 2007; 2:1-16. PMID: 23641142; PMCID: PMC3634709.
    Citations: 5     
  122. Moss AC, Treister NS, Marsee DK, Cheifetz AS. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab. Gastroenterology. 2007 Feb; 132(2):488, 829. PMID: 17261307.
    Citations: 3     Fields:    Translation:Humans
  123. Moss AC, Morris E, Leyden J, MacMathuna P. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev. 2007 Apr; 33(2):213-21. PMID: 17157990.
    Citations: 39     Fields:    Translation:Humans
  124. Moss AC, Farrell RJ. Infliximab for induction and maintenance therapy for ulcerative colitis. Gastroenterology. 2006 Nov; 131(5):1649-51; discussion 1651. PMID: 17067595.
    Citations: 2     Fields:    Translation:Humans
  125. Leyden JE, Moss AC, MacMathuna P. Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev. 2006 Oct 18; (4):CD005046. PMID: 17054234.
    Citations: 27     Fields:    Translation:Humans
  126. Kokkotou E, Torres D, Moss AC, O'Brien M, Grigoriadis DE, Karalis K, Pothoulakis C. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol. 2006 Sep 01; 177(5):3355-61. PMID: 16920976.
    Citations: 38     Fields:    Translation:HumansAnimalsCells
  127. Moss AC, Cheifetz AS, Peppercorn MA. Combined oral and topical mesalazine treatment for extensive ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006 May; 3(5):290-3. PMID: 16673009.
    Citations: 2     Fields:    Translation:Humans
  128. Moss AC, Lawlor G, Murray D, Tighe D, Madden SF, Mulligan AM, Keane CO, Brady HR, Doran PP, MacMathuna P. ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. Biochem Biophys Res Commun. 2006 Jun 23; 345(1):216-21. PMID: 16678123.
    Citations: 12     Fields:    Translation:HumansCells
  129. Leyden J, Murray D, Moss A, Arumuguma M, Doyle E, McEntee G, O'Keane C, Doran P, MacMathuna P. Net1 and Myeov: computationally identified mediators of gastric cancer. Br J Cancer. 2006 Apr 24; 94(8):1204-12. PMID: 16552434; PMCID: PMC2361249.
    Citations: 22     Fields:    Translation:HumansCells
  130. Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev. 2006 Apr 19; (2):CD004200. PMID: 16625598.
    Citations: 13     Fields:    Translation:Humans
  131. Moss AC, Farrell RJ. Lymphoma risk with azathioprine/6-MP therapy-read beyond the headlines. Gastroenterology. 2006 Apr; 130(4):1363-4. PMID: 16618430.
    Citations:    Fields:    
  132. Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev. 2006 Jan 25; (1):CD004200. PMID: 16437477.
    Citations: 47     Fields:    Translation:Humans
  133. Moss AC, Brennan AM, Cheifetz AS, Peppercorn MA. Thyroid cancer and Crohn's disease: association or coincidence? Inflamm Bowel Dis. 2006 Jan; 12(1):79-80. PMID: 16374265.
    Citations: 3     Fields:    Translation:Humans
  134. Moss AC, Farrell RJ. Adding fuel to the fire: GM-CSF for active Crohn's disease. Gastroenterology. 2005 Dec; 129(6):2115-7. PMID: 16344081.
    Citations: 1     Fields:    Translation:Humans
  135. Moss AC, Dugal T, Silke B. Attitudes to peer review as a competence assurance structure--results of a survey of Irish physicians. Ir J Med Sci. 2005 Jul-Sep; 174(3):43-6. PMID: 16285338.
    Citations:    Fields:    Translation:Humans
  136. Bruzzi JF, Moss AC, Brennan DD, MacMathuna P, Fenlon HM. Colonic surveillance by CT colonography using axial images only. Eur Radiol. 2004 May; 14(5):763-7. PMID: 14986051.
    Citations: 6     Fields:    Translation:Humans
  137. Bruzzi JF, Moss AC, Brennan DD, MacMathuna P, Fenlon HM. Efficacy of IV Buscopan as a muscle relaxant in CT colonography. Eur Radiol. 2003 Oct; 13(10):2264-70. PMID: 12942279.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  138. Bruzzi JF, Moss AC, Fenlon HM. Clinical results of CT colonoscopy. Eur Radiol. 2001; 11(11):2188-94. PMID: 11702159.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Moss's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (461)
Explore
_
Co-Authors (52)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.